Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.10
Bid: 1.93
Ask: 2.11
Change: 0.12 (6.32%)
Spread: 0.18 (9.326%)
Open: 1.80
High: 2.10
Low: 1.80
Prev. Close: 1.90
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

Tue, 24th Nov 2020 21:30

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Gore Street Energy Storage Fund PLC - investor in utility-scale energy storage projects - Energises its 50 megawatt installed capacity Drumkee project in Northern Ireland. Drumkee becomes the largest energy storage project in Ireland. Expects its second 50 megawatt project, Mullavilly, to be energised in December. Both projects to be commissioned and operational in first quarter of 2021, taking portfolio's total installed capacity to 210 megawatts. "Notwithstanding the Covid lockdown and severe restrictions on movement, both project completion dates currently remain on schedule and budget."

----------

Martin Currie Global Portfolio Trust PLC - investment company focused on long-term returns in excess of the total return from the MSCI All Cos World index - Agrees draw down in full on unsecured three-year GBP30 million Royal Bank of Scotland International Ltd term loan with 1.181% fixed interest rate. Drawdown takes place on Tuesday. Loan represents around 10% of current net asset value.

----------

Immupharma PLC - London-based pharmaceutical company - Lind Global Macro Fund LP converts USD355,113 plus accrued unpaid interest of convertible security. This relates to convertible security deed from June 2020. Conversion price 11 pence per share, resulting in issue by Immupharma of 2.5 million shares.

----------

Helios Underwriting PLC - Lloyd's of London insurer - Receives valid acceptances for 252,843 open offer shares including applications under excess application facility. This represents 18% of open offer share available and raises GBP303,412. Non-Executive Chair Michael Cunningham and Non-Executive Director Andrew Christie subscribe for open offer entitlement of 6,053 and 2,392 open offer shares respectively.

----------

Block Energy PLC - exploration and production company focused on Georgia - Completes acquisition of Schlumberger Rustaveli Co Ltd and now holds licences for Georgian onshore blocks IX and XI. Company will now commence integration process and implement cost reduction plan. Has continues subsurface technical studies of Schlumberger Rustaveli assets "yielding economically attractive short and medium-term opportunities." Intends to apply for permits for workover and drilling programme across XI and West Rustavi licence areas.

----------

Uniphar PLC - healthcare services firm - Acquires RRD International, a US-based pharmaceutical advisory group that provides outsources consulting and execution services throughout early stages of product development. Purchase price includes upfront payment as well as contingent payment payable on achievement of earnings before interest, tax, depreciation, and amortisation-based targets. Acquisition expected to deliver return on capital employed in line with Uniphar's 12% to 15% target rate within three years. Further financial details not disclosed. Says: "acquisition will facilitate the growing requirement for Uniphar's delivery of US based expanded access programmes."

----------

Keras Resources PLC - mineral resource company - Notes that Chief Executive Russell Lamming has recently returned from Lome, Togo where he met with key government officials including Minister of Mines & Energy Mila Aziable and Minister of Investment Promotion Kayi Mivedor. Follow-up meetings also took place with state-owned Togo Invest Corp SA, which is helping assist with permitting process for the Nayega manganese mine in Northern Togo. Nayega is wholly owned by Kera's 85% owned Societe Generale de Mines subsidiary. Chief Executive Russell Lamming says: "Constructive meetings were undertaken with both the ministries of Mines and Energy and Investment Promotion during my recent trip to Togo; I expect to get feedback in the near term on what the pathway to final permitting at Nayega comprises."

----------

Lidco Group PLC - London-based hemodynamic monitoring company - As of Monday this week, Masimo has received valid acceptances in respect of 183.2 million Lidco shares, which it has acquired. These shares represent around a 75% stake in Lidco's existing issue share capital. Offer extended for 14 days and will stay open for acceptances until December 7. As announced November 2, Lidco has agreed to be acquired for GBP31.1 million, or 12 pence per share.

----------

FastForward Innovations Ltd - Guernsey-based closed-ended investment company - Notes update from hemp and CBD social commerce wellness company Yooma Corp, in which it holds a 10.65% stake. Yooma is launching clean CBD beauty brands MASK Skincare and Lab to Beauty ahead of the Black Friday and 12.12 China e-commerce events. These are being launched on BorderX Lab's China cross-border eCommerce app, Beyond. FastForward Chief Executive Ed McDermott: "We look forward to providing further updates regarding Yooma's commercial progress and its proposed merger with TSX quoted Globalive Technology Inc."

----------

Tern PLC - AIM-listed London-based investment firm specialising in internet of things - Portfolio company FVRVS Ltd secures GBP400,000 three-year contract with existing client. Client is an undisclosed "global pharmaceutical company". Contract to deliver recurring annual revenues over term from licences and support, enabling global rollout of the client's training solution using FundamentalVR's Fundamental Surgery virtual reality platform. Deal follows an initial GBP500,000 contract announced December 2019.

----------

Nippon Active Value Fund PLC - Japan-focused investment firm - Net asset value per share loses 0.5% to 105.03 pence over four months ended October 31 while share price reflects 10% discount to NAV. Since month end, both NAV per share and share price up, with NAV per share on November 16 being 109.33p and share price totalling 105p, with discount narrowed to 4%. Paul ffolkes Davis, chair of investment adviser Rising Sun Management, says: "There have been a myriad of recent articles on the changing landscape in Japan for corporate activity and consolidation of smaller, cash-rich companies. Certainly our initial engagement with [Ebara Jitsugyo] suggests these companies are susceptible to focused shareholder intervention - the auguries for NAVF's ongoing campaign look bright."

----------

Armadale Capital PLC - investment company focused on natural resource projects in Africa - Picks Xinhai Mineral EPC, part of Chinese Yantai Xinhai group, to begin metallurgical bulk test work as part of the first phase of front-end engineering design studies for its Tanzanian Mahenge graphite project. Aim of work is to provide enough data to confirm result underpinning definitive feasibility study and confirm the preferred flow sheet before FEED completion. First bulk samples received by Xinhai.

----------

Urban Exposure PLC - residential development firm and asset manager - Plans shortly to proceed with tender offer for up to GP65 million in value of Urban Exposure shares at 75 pence per share. Completion of this tender offer is subject to shareholder approval. As previously disclosed, tangible net asset value as at June 30 was 77p per share with tender price representing a 2.6% discount to tangible NAV but a 7.9% premium to mid-market price of 69.50p per share at close of business on Monday. Company's current cash balance is GBP81 million.

----------

CATCo Reinsurance Opportunities Fund Ltd - Investor focused on offering returns from investments linked to catastrophe reinsurance risks - Has been advised of additional release of side pocked investment capital totalling around USD8 million. This is set to be paid to the company in January 2021, with CATCo planning to use the funds for a six compulsory redemption of shares. Updates breakdown of payments to ordinary shareholders is approximately USD2 million, with around USD6 million to C shareholders. Notes that subsequent to approval, and including sixth redemption, it will have returned around USD271.3 million to shareholders through compulsory redemptions, dividend, a tender offer and share buybacks.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
14 Sep 2022 12:46

IN BRIEF: ImmuPharma receives response for FDA for Lupuzor

ImmuPharma PLC - specialist drug discovery and development company - Says its US partner for Lupuzor, Avion Pharmaceuticals LLC, has received a written response from the US Food & Drug Administration that provided detailed guidance on the next steps for the drug's clinical programme. This included advice on the dosing regime, as well as guidance on the study protocol that can be amended to improve the regulatory outcome.

Read more
7 Sep 2022 09:55

ImmuPharma raises GBP150,000 via issue of 3 million new shares

ImmuPharma PLC - specialist drug discovery and development company - Says L1 Capital Global Opportunities Master Fund has exercised options over 3.0 million new shares at a price of 5 pence each, for GBP150,000 in total. The new shares represent 0.9% of the company's enlarged share capital.

Read more
31 Aug 2022 21:41

TRADING UPDATES: ImmuPharma waits on FDA; IDE Group waits on audit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Aug 2022 19:08

IN BRIEF: ImmuPharma raises GBP950,000 from broker option

ImmuPharma PLC - specialist drug discovery and development company - Raises GBP950,000 under broker option, taking total proceeds from placing and broker option to GBP1.04 million. "Further to the announcement of August 3, 2022, the directors confirm that the fundraising, together with existing funding and funding arrangements, will provide the company with sufficient working capital for at least the next 12 months," it says.

Read more
3 Aug 2022 19:40

IN BRIEF: ImmuPharma to raise funds for investment into pipeline

ImmuPharma PLC - specialist drug discovery and development company - Intends to raise GBP1.1 million through the placing and subscription of 21.8 million shares at a price of 5.0 pence per share.

Read more
7 Jul 2022 20:35

IN BRIEF: ImmuPharma US partner gets Type C meeting with US FDA

ImmuPharma PLC - specialist drug discovery and development company - Says Avion Pharmaceuticals, its US partner for its Lupuzor lupus treatment, received a Type C Meeting confirmation from the US Food & Drug Administration. The London-listed company says statement of purpose, objectives and proposed agenda of the meeting have already been agreed on, as has the option to provide written responses, rather than face-to-face meetings. The FDA has agreed to provide a written response by August 29.

Read more
21 Jun 2022 16:05

UK shareholder meetings calendar - next 7 days

Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Union Jack Oil PLCAGM
Zinnwald Lithium PLCAGM
Friday 24 June 
AFC Energy PLCGM re fees for non-executive directors
Avast PLCAGM
Devolver Digital IncAGM
Entain PLCAGM
Gulf Keystone Petroleum LtdAGM
Hawkwing PLCAGM
Invesco Bond Income Plus LtdAGM
Life Science REITAGM
Northcoders Group PLCAGM
Princess Private Equity Holding LtdAGM
Monday 27 June 
Anglo-Eastern Plantations PLCAGM
Celadon Pharmaceuticals PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Echo Energy PLCAGM
Medica Group PLCAGM
Pelatro PLCAGM
Surgical Innovations Group PLCAGM
Warpaint London PLCAGM
Tuesday 28 June 
4D Pharma PLCAGM
Acceler8 Ventures PLCAGM
Airtel Africa PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Attraqt Group PLCAGM
Bay Capital PLCAGM
Capital & Counties Properties PLCAGM
CMO Group PLCAGM
Corre Energy BVAGM
Creo Medical Group PLCAGM
Futura Medical PLCAGM
Gama Aviation PLCAGM
ICG Enterprise Trust PLCAGM
ImmuPharma PLCAGM
IQE PLCAGM
Katoro Gold PLCAGM
Rockhopper Exploration PLCAGM
Sound Energy PLCAGM
TP Group PLCAGM
UK Oil & Gas PLCAGM
Volvere PLCAGM
Zegona Communications PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
25 May 2022 16:53

IN BRIEF: ImmuPharma shares fall as annual loss widens

ImmuPharma PLC - specialist drug discovery and development company - Widens its pretax loss to GBP8.9 million in 2021 from GBP7.2 million loss the previous year. Loss includes exceptional costs in respect of corporate reorganisation and respective settlement arrangements, company adds. Revenue drops 6.6% to GBP118,350 from GBP126,667. Research and development expenses surge to GBP3.7 million from GBP2.4 million. P140-related expenditure was the main reason for this increase. P140, also known as Llupuzor, is a potential treatment for Lupus. Company does not propose a dividend.

Read more
6 May 2022 19:11

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
4 May 2022 13:03

ImmuPharma making final preparations for Lupuzor phase 3 trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Wednesday that final preparations were now underway to progress 'Lupuzor' into its new, optimised international phase 3 trial in lupus patients.

Read more
13 Apr 2022 13:54

ImmuPharma surges on success in latest trial of lupus treatment

(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported positive data from its 'Lupuzor' pharmacokinetic study on Wednesday, as part of the new, optimised international third phase trial in lupus patients.

Read more
13 Apr 2022 12:09

IN BRIEF: Immupharma shares soar on positive data from lupus study

Immupharma PLC - London-based drug discovery and development company - Says its Lupuzor/P140 pharmacokinetic study, required by the US Food & Drug Administration, has met the key endpoints requested. The study is part of an international phase 3 trial of the Lupuzor treatment for patients with lupus disease. The dosing of healthy subjects started on February 15 and showed that P140 was safe and well-tolerated across all doses and in all subjects. Notes that the positive data now clears the path for the start of all clinical studies within the P140 platform. Adds that there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy, a rare neurological disorder.

Read more
13 Apr 2022 11:06

AIM WINNERS & LOSERS: ImmuPharma hits milestone; Shearwater contract

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
7 Feb 2022 18:29

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

Read more
7 Feb 2022 13:13

ImmuPharma updates plan for trials of lupus treatment Lupuzor

(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on the pharmacokinetic study of 'Lupuzor' on Monday, as part of the new, optimised international phase 3 trial of Lupuzor in lupus patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.